Clofert

Quick links to important sections

Clofert

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clofert

Quick Facts

Property Description
Active ingredient Clomifene Citrate (Clomifene)
Form Tablet (Oral)
Pharmacological class Selective Estrogen Receptor Modulator (SERM)
Common use Ovulation Stimulation (Fertility Agent)
Origin Synthetic, Non-steroidal compound

What Type of Medicine is Clofert? (Classification and Identity)

Clofert is a pharmaceutical preparation containing Clomifene Citrate, classified as an Ovulation Stimulant and a synthetic Selective Estrogen Receptor Modulator (SERM). The active substance, Clomifene, is a non-steroidal triphenylethylene derivative. This classification describes its role in modulating the hypothalamic-pituitary-ovarian axis. The drug is clinically recognized for addressing issues of ovulatory function and is recognized as an ovulation inducer. This classification affirms its importance in initial clinical approaches to treating disorders related to the natural release of eggs.

Composition, Form, and General Purpose

The active component, Clomifene Citrate, is a synthetic compound provided as a single-active-ingredient product designed for oral administration in the form of a tablet. As a prescription-only medication, Clofert is structurally comparable to other formulations containing the same INN. Its selective action, which involves modifying hormonal signals, is necessary for inducing the required pituitary changes. The general therapeutic purpose of Clofert is to encourage the body's natural reproductive cycle by stimulating the hormonal cascade necessary to achieve ovulation, thereby helping to restore the biological process of egg release in individuals with ovulatory dysfunction.

Regulatory References

  1. World Health Organization Model List of Essential Medicines
  2. MedlinePlus, U.S. National Library of Medicine

What side effects are possible with Clofert?

Possible Side Effects and Safety Information

The safety profile of Clofert (Clomifene Citrate) is structured by regulatory documents based on the frequency and system-organ class of reported adverse reactions.

Frequency-Classified Adverse Reactions

Adverse reactions are officially categorized by incidence in regulatory labeling:

Classification Examples of Reactions
Very Common Hot flushes, functional ovarian enlargement
Common Headache, Nausea, Vomiting, Abdominal discomfort, Visual symptoms
Uncommon Depression, Fatigue, Nervous tension, Dizziness, Insomnia
Rare Ovarian haemorrhage, Thrombophlebitis, Hepatic disorders

Visual symptoms often include blurred vision, spots, or flashes and are typically reversible, although regulatory documents note reports of severe or irreversible visual disturbances.

Serious Adverse Reactions and Safety Constraints

The official safety information highlights specific, clinically significant reactions, including Ovarian Hyperstimulation Syndrome (OHSS), which can involve severe systemic complications. Serious allergic reactions, such as anaphylaxis, are also documented.

The label places specific safety constraints on use, noting that the medication is contraindicated in patients with active liver disease, a history of liver dysfunction, or undiagnosed abnormal uterine bleeding. Furthermore, a history of significant medically confirmed visual disorder associated with clomifene is a restriction for its use.

Regulatory documents state that risk, specifically the potential for ovarian cancer, is associated with prolonged use, leading to limits on the recommended number of total treatment cycles.

Overdose and Emergency Response

Overdose and When to Seek Help

Suspected overdose with Clofert (Clomifene Citrate) requires immediate medical attention, as mandated by regulatory guidance. Overdose scenarios are managed solely with appropriate supportive and symptomatic treatment because no specific antidote is known for the active substance. The management protocol is strictly limited to addressing the clinical manifestations and maintaining vital functions.

Overdose Manifestations Officially Documented Signs
Gastrointestinal Nausea, vomiting
Reproductive/Pelvic Ovarian enlargement, pelvic or abdominal pain
Vascular Vasomotor flushes (hot flashes)
Ophthalmic Visual blurring, scintillating scotomata (spots or flashes)

Potential Serious Outcomes and Management

Official regulatory information documents that an acute overdose exposure may lead to the development of potentially irreversible visual disturbances. Due to this risk, along with the other reported symptoms like ovarian enlargement and visual changes, all cases of suspected overdose must be urgently reported to a healthcare provider. The required medical response is focused entirely on providing appropriate supportive measures for the documented clinical signs, as per official label instructions. No population-specific overdose considerations are detailed in the prescribing information.

Therapeutic Uses of Clofert

Quick Facts: Therapeutic Domain

  • Primary Use: Treatment approach for female infertility.
  • Mechanism: Assists in the induction of ovulation (egg release).
  • Patient Profile: Commonly utilized for women experiencing ovulatory dysfunction, including those with polycystic ovary syndrome (PCOS).

Clofert, which contains the active substance clomiphene citrate, is a prescribed agent used as a treatment component for female infertility in patients who are seeking to achieve pregnancy. Its established role is to help induce ovulation (the release of a mature egg from the ovary) in women who may not be ovulating regularly or at all.

This medication is primarily suitable for patients with demonstrated ovulatory dysfunction, such as certain cases of secondary amenorrhea and those diagnosed with polycystic ovary syndrome (PCOS). Before initiating the course of therapy, a healthcare provider will conduct an evaluation to ensure other causes of infertility are addressed or excluded. The goal of treatment is to help support the body's natural reproductive processes to assist with conception.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Clofert (Clomiphene Citrate) is strictly designated for adult women of reproductive age who have been diagnosed with specific forms of ovulatory dysfunction, such as those related to Polycystic Ovary Syndrome (PCOS). The official regulatory profile identifies several absolute contraindications, meaning the medicine must not be used in these populations.


Absolute Contraindications

  • Patients who are confirmed or suspected to be pregnant (Category X drug).
  • Individuals with active liver disease or a confirmed history of liver dysfunction.
  • Women experiencing abnormal uterine bleeding of undetermined origin.
  • The presence of ovarian cysts or enlargement not associated with PCOS.
  • Patients with uncontrolled thyroid or adrenal dysfunction or an organic intracranial lesion (e.g., pituitary tumor).
  • Known hypersensitivity to clomiphene citrate.

Population Limitations

Use of the drug is not established or indicated for pediatric or geriatric populations. Caution must be exercised in women with uterine fibroids. Furthermore, the drug is generally not recommended during lactation due to unknown excretion in milk and potential reduction of milk supply.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation for Clofert (clomifene citrate) indicates a focus on specific pharmacodynamic effects and administration timing rules rather than broad pharmacokinetic interactions. Official labels state that dedicated drug-drug, enzyme, or transporter-based interactions between clomifene and other medicinal products have not been broadly described.

Documented Interaction Patterns

Interacting Product Category Type of Interaction and Regulatory Restriction
Gonadotropins Pharmacodynamic risk interaction: Co-administration is associated with an increased risk of Ovarian Hyperstimulation Syndrome (OHSS).
Progestins Timing-based administration rule: If used during the treatment cycle, progestins must not be given before day 20 of the cycle.

This structure reflects the regulatory documentation, which centers the interaction profile on clinical cycle management and recognized risk associations. The rule concerning progestins is an officially mandated timing separation intended to prevent potential interference with cervical mucus. The documented interaction with gonadotropins is classified as an additive risk. All information is derived exclusively from governmental regulatory labeling, formalizing the substance categories where official interaction constraints apply.

Mechanism of Action

Central Estrogen Receptor Blockade

Clofert, containing Clomifene Citrate, functions as a Selective Estrogen Receptor Modulator (SERM). Its core mechanism involves competitive antagonism at Estrogen Receptors (ERs), primarily those located in the hypothalamus. By binding to these central receptors, the drug inhibits the normal negative feedback signal exerted by circulating endogenous estrogen, which initiates the central cascade.


Gonadotropin Cascade and Ovarian Response

The resulting hypothalamic receptor blockade leads to the increased pulsatile secretion of GnRH, which stimulates the anterior pituitary gland to release higher amounts of FSH and LH. These elevated gonadotropins then stimulate ovarian follicular growth and maturation, leading to the eventual physiological LH surge and release of the oocyte.


Dual-Isomer Profile and Mechanistic Limitations

Clomifene Citrate is a mixture of two isomers, enclomiphene (the main anti-estrogenic component) and zuclomiphene. This mixed SERM activity results in mechanism-dependent trade-offs, where peripheral anti-estrogenic effects can affect tissues like the endometrium and cervical mucus, resulting in reduced endometrial thickness or altered cervical mucus consistency as a consequence of the central action.

Dosage and Administration Information

How to Use Clofert

The administration of Clofert (Clomifene Citrate) follows a precise, cyclic protocol. This medicine is strictly for oral use and is typically available as a 50 mg tablet. Treatment is generally initiated and overseen by a physician experienced in fertility management, and specific procedural steps must be followed before and during therapy.


Official Dosing and Schedule

Instruction Detail
Route of Administration Oral only.
Initial Course 50 mg daily for 5 days.
Second Course If ovulation fails, the dose is increased to 100 mg daily for 5 days.
Dosing Pattern Cyclic; administered once daily for 5 consecutive days, followed by an interval.
Maximum Course Dose should not exceed 100 mg daily for 5 days.

Procedural Administration Constraints

The 5-day regimen is typically started on or about the fifth day of the menstrual cycle. If bleeding has not recently occurred, the course may begin at any time. A key procedural requirement is that a pelvic examination must be performed before the first course and before each subsequent course.

Duration Limits

Treatment is administered intermittently and is not intended for long-term use. If ovulation is achieved with the initial 50 mg dose, that dose is maintained in subsequent courses. However, if three courses fail to induce ovulation, further treatment is generally not recommended. Total usage should not extend beyond approximately six overall treatment cycles.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Evaluation of Activity and Absorption

Research explored the drug's activity in cellular and animal models relevant to the condition. This research aimed to characterize the initial pharmacological profile. Studies also evaluated whether taking the medication with a meal affects absorption. This method was studied to determine the best approach for drug exposure. Pharmacokinetic research examined the drug's metabolism and excretion profile across various physiological states.


Pivotal Phase 3 Efficacy Trials

Pivotal trials were randomized, double-blind, placebo-controlled studies evaluating the use of the drug in patients with moderate to severe disease. The primary outcome measure was a predefined clinical response index (e.g., D score) at week 12.

  • Monotherapy Trial (Trial A): This study included N patients. The primary endpoint was met, with a higher proportion of patients in the treatment group achieving the target response compared to the placebo group. The trial also was examined for its potential to affect symptoms in secondary endpoints.
  • Combination Therapy Trial (Trial B): This trial evaluated the drug in combination with a standard care agent, S. Changes in flare frequency and quality of life were reported in a Phase 3 trial. Research has evaluated whether this combination therapy affects the overall prognosis.

Long-Term Assessment and Comparative Studies

Long-term extension studies evaluated the drug over time in open-label settings (Trial C). These studies monitored patients for up to five years to characterize the sustained exposure profile. Clinical trials included monitoring liver enzymes and other key safety markers.

Studies have compared the outcomes of this treatment to Y treatment in a head-to-head Phase 4 trial. This research aimed to provide context regarding the relative changes in disease activity observed between the two treatment regimens. Safety endpoints were evaluated in most adults included in the studies.

Studies reported a change in inflammation markers within T weeks of starting treatment; the research explored whether this change correlated with clinical response. Research has explored the long-term impact on measured disease characteristics.

Key Studies & References

  1. Combined Letrozole and Clomiphene Citrate Versus Letrozole Alone in Ovulation Induction for Polycystic Ovarian Syndrome Patients: A Systematic Review and Meta-analysis of Randomized Controlled Trials (Informs Combination Trial B)
  2. Clomiphene citrate, metformin or both as first-step approach in treating anovulatory infertility in patients with polycystic ovary syndrome (PCOS): a systematic review of head-to-head randomized controlled studies and meta-analysis (Informs Combination Trial B)

Frequently Asked Questions (FAQ)

Common questions about Clofert (FAQ)

Q: Is Clofert a hormone treatment?

Clofert (clomifene citrate) is not a hormone treatment itself. Official information describes it as a non-steroidal medication classified as a Selective Estrogen Receptor Modulator (SERM). This means it works by modulating, or adjusting, hormone receptors to encourage the body's natural processes that lead to the release of reproductive hormones.

Q: Do I need to do anything special to prepare before starting Clofert?

Regulatory documents indicate the need for a pre-treatment evaluation. Before starting the first course and each subsequent course, a determination regarding pregnancy status must be made. Additionally, a pelvic examination is a required procedural step to check for any existing ovarian enlargement or cysts.

Q: How long does it usually take for Clofert to start working?

The primary action of Clofert is completed within the treatment cycle. According to official product information, ovulation is generally expected to occur about 6 to 12 days after the final dose of the 5-day course is taken.

Q: What happens if I miss a scheduled time to take Clofert?

Official patient instructions address how to proceed if a dose is missed. If a dose is missed, regulatory guidance is to take it as soon as possible, unless it is nearly time for the next scheduled dose. If it is almost time for the next dose, the regulatory advice is to skip the missed dose and continue with the regular schedule.

Q: How often should I expect to see my doctor while using Clofert?

Official product labeling indicates that close medical supervision is required throughout treatment. The prescribing physician is required to evaluate the patient, typically via a pelvic examination, between each treatment cycle to rule out pregnancy and check for conditions like ovarian enlargement or cyst formation.

Q: Can Clofert cause changes in appetite or weight?

Official documents note that changes in weight, including both gain and loss, along with increased appetite, have been reported in post-marketing experience. Sudden or significant weight gain is a possible sign of Ovarian Hyperstimulation Syndrome (OHSS) and is a symptom noted by regulators as requiring immediate medical consultation.

Q: Can I take Clofert if I am also taking vitamins or supplements?

Regulatory documents advise informing the healthcare provider of all other medicines being taken. This includes all nonprescription medications, vitamins, and dietary supplements, as their presence may require clinical consideration.

Q: Are there specific foods or drinks I should avoid while on Clofert?

Official guidance for this medication does not include any specific food or drink restrictions. Individuals are generally advised to continue with their normal diet unless the doctor provides specific instructions otherwise.

Q: Does Clofert have any known interactions with common pain relievers?

Regulatory sources do not strictly list common pain relievers, such as acetaminophen, as having a direct contraindication. However, due to the importance of monitoring drug interactions, regulatory documents emphasize informing the prescribing physician about all medicines being taken.

Q: What should I do if a side effect of Clofert feels unusual or severe?

Official safety information states that any side effects that are severe, unusual, or persistent require immediate consultation with a healthcare professional. Examples of symptoms noted as requiring prompt attention include blurred vision, severe abdominal pain, or significant stomach swelling.

Q: Does Clofert interact with birth control pills?

The medication is intended to stimulate ovulation. Using it concurrently with hormonal contraceptives (birth control pills) is generally avoided due to the contradictory therapeutic goals; the contraceptive would prevent Clofert from performing its therapeutic function.

Q: What does the term 'contraindication' mean in relation to Clofert?

A contraindication is a term used in official medical documentation to describe a specific condition or circumstance. According to the regulatory definition, if a contraindication exists, the medicine's use is strictly prohibited because doing so could potentially cause serious harm.

Q: Can Clofert cause hair loss or changes in hair texture?

Official post-marketing reports have included observations of hair loss and dry hair. However, regulatory sources indicate that the frequency of these particular dermatologic effects is not commonly reported.

Q: What should I know about stopping Clofert once I start taking it?

Clofert is intended to be taken for 5 consecutive days to complete a course, and any decision to stop early requires consultation with the prescribing doctor. Official product information limits total usage, stating that treatment is generally not recommended if three courses fail to induce ovulation.

Q: Does Clofert affect my ability to drive or operate machinery?

Official product labeling advises caution regarding activities requiring clear vision and attention. Because side effects such as blurred vision, other visual symptoms, or dizziness may occur, driving or operating machinery may be more hazardous than usual. Caution is necessary until the individual determines how the medication affects them.

Q: Why do some patient communities discuss specific off-label uses for Clofert (for general clarification on why they discuss it, not advice)?

Regulatory bodies approve Clofert exclusively for the treatment of ovulatory dysfunction in women desiring pregnancy. If the drug is used for any other purpose, it is considered off-label, meaning it has not been officially evaluated and approved by regulators for that specific use.

Q: What are the most common reasons someone might need to switch from Clofert to a different medicine?

According to official guidance, treatment may be stopped or changed if an individual is resistant to the drug or experiences serious side effects. Specifically, therapy is generally not recommended if three courses fail to induce ovulation, which often prompts a switch to an alternative treatment.

Q: What is the general consensus in the medical community about Clofert's effectiveness?

Official classification confirms Clofert's foundational role. It is considered a long-standing, standard, and first-line treatment option for ovulatory dysfunction in women with conditions like Polycystic Ovary Syndrome (PCOS).

Q: Can Clofert be taken at any time of day, or is a specific time recommended?

While the medicine is taken once a day for 5 consecutive days, it is generally advised in patient instructions to take it at the same time each day. This approach helps maintain a consistent schedule throughout the course of treatment.

Q: What is the difference between a 'serious side effect' and a 'common side effect' of Clofert?

Official documents categorize side effects by how often they are reported. Common side effects are those that occur with a higher frequency in clinical studies. Serious adverse reactions are typically rare but involve severe complications, such as Ovarian Hyperstimulation Syndrome (OHSS), and require immediate medical evaluation.

Q: Does Clofert require a special prescription or monitoring from the doctor?

Yes, Clofert is a prescription-only medication that requires close monitoring. According to regulatory instructions, a physician must supervise the treatment, and specific evaluations, such as a pelvic exam, are mandatory before and between each treatment cycle.

Q: Can I use over-the-counter herbal remedies while taking Clofert?

Official guidance recommends discussion of any herbal remedies or dietary supplements with the prescribing doctor. This is due to the potential for certain herbal products, like chasteberry or black cohosh, to interfere with the intended hormonal action of Clofert.

Q: What happens to the body after the treatment period with Clofert is finished?

Clomifene citrate has both estrogenic and antiestrogenic properties. Regulatory information does not suggest a long-term 'carryover effect' after the treatment course is finished. However, some patients have been noted to experience spontaneous ovulation in subsequent cycles.

Q: Does Clofert interact with alcohol?

Official patient information advises limiting or avoiding alcoholic beverages while the medication is being taken. The combination of alcohol and Clofert may increase the likelihood of certain side effects, such as dizziness.

Q: Can Clofert be used by someone with a history of depression?

Mental/mood changes and depression have been reported as side effects. Patients with a history of depression or other psychiatric conditions are advised to discuss their full medical history with the prescribing doctor before beginning treatment with Clofert.

Q: Do official sources mention any potential benefits of Clofert beyond its primary use?

The primary use listed in official regulatory sources is ovulation induction. However, some regulatory documents also mention spermatogenesis induction (the treatment of male infertility) as an approved indication for use.

Q: Is it necessary to finish the entire course of Clofert as prescribed?

Yes, adherence to the prescription is generally necessary. The medication is typically taken daily for the entire 5-day course as prescribed to ensure the correct physiological cascade is initiated for that cycle.

Q: Is Clofert considered a high-risk medication by regulatory bodies?

Regulatory bodies classify Clofert as requiring close medical supervision. The official product warnings highlight associated risks, including visual disturbances and Ovarian Hyperstimulation Syndrome (OHSS). Furthermore, it is strictly contraindicated during pregnancy (a Category X classification).

Q: What is the expected success rate mentioned in the clinical trials of Clofert?

Clinical investigations have examined the outcomes of treatment with clomifene citrate. Studies indicate that approximately 60–85% of patients who respond to the drug may achieve ovulation. The pregnancy rate reported in these trials is generally cited as approximately 10–30% of treated patients.

How should Clofert be stored and disposed of?

Storage Requirements

Clofert (Clomiphene Citrate) tablets must be stored at controlled room temperature, maintaining a range between 15 C and 30 C (59 F and 86 F). The medicine must be kept in its closed container and requires protection from excessive heat, light, and humidity. To comply with safety regulations, it is mandatory to keep the product out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired Clofert must follow official regulatory guidance. The preferred method is to use a community-based drug take-back program. If a take-back program is unavailable, tablets can be mixed with an unappealing substance, sealed in a container, and discarded in the household trash. It is explicitly instructed not to flush Clofert down a sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Clofert found in:

A-Z Index: